Development Pipeline

Navicixizumab Etigilimab GITRL-Fc


OncoMed currently has three therapeutic candidates in active clinical development targeting cancer stem cell pathways and immuno-oncology. OncoMed is also pursuing discovery of additional novel approaches to cancer treatment, including new immuno-oncology therapeutic candidates. All of the therapeutic candidates in our pipeline were discovered by OncoMed scientists.


Navicixizumab (Anti-DLL4/VEGF bispecific, OMP-305B83)

Navicixizumab, OncoMed's anti-DLL4/VEGF bispecific antibody targets both DLL4 in the Notch cancer stem cell pathway and vascular endothelial growth factor (VEGF). This antibody is intended to have anti-angiogenic plus anti-cancer stem cell and immunomodulatory activity. In a Phase 1a clinical trial, navicixizumab demonstrated single-agent anti-tumor activity and was safe enough to be administered on a continuous basis. OncoMed is currently conducting a Phase 1b clinical trial of navicixizumab in combination with paclitaxel in patients with heavily pretreated platinum-resistant ovarian cancer.

Information on navicixizumab clinical trials is available here: Navicixizumab

Public presentations of studies on navicixizumab include:


Etigilimab (Anti-TIGIT, OMP-313M32)

TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor that is thought to stop T-cells from attacking tumor cells, similar to the inhibitory protein PD-1. OncoMed's anti-TIGIT therapeutic candidate etigilimab is intended to activate the immune system through multiple mechanisms and enable anti-tumor activity. A Phase 1a/b clinical trial of OncoMed's anti-TIGIT candidate is currently enrolling patients.

Information on OncoMed's anti-TIGIT clinical program is available here: OMP-313M32

This program is part of OncoMed's collaboration with Celgene Corporation.

Public presentations of data from OncoMed's anti-TIGIT program include:


GITRL Trimer Fc (OMP-336B11)

GITRL is a member of the tumor necrosis factor (TNF) family of ligands and functions to activate the co-stimulatory receptor GITR (glucocorticoid-induced tumor necrosis factor receptor) to enhance T-cell modulated immune responses. OncoMed's GITRL-Fc therapeutic candidate is engineered using a novel single-gene linkerless GITRL trimer technology that is designed to enable effective GITR activation. In preclinical models, OncoMed's GITRL-Fc therapeutic candidate has achieved robust anti-tumor immune responses alone and in combination with other immuno-oncology agents. A Phase 1a clinical trial of OncoMed's GITRL-Fc therapeutic candidate is currently active and enrolling patients.

Information on OncoMed's GITRL clinical program is available here: OMP-336B11

Public presentations of data from OncoMed's GITRL program include: